{
    "clinical_study": {
        "@rank": "168349", 
        "acronym": "EVERKYSTE", 
        "arm_group": [
            {
                "arm_group_label": "Everolimus", 
                "arm_group_type": "Experimental", 
                "description": "everolimus based immunosuppression"
            }, 
            {
                "arm_group_label": "Calcineurin", 
                "arm_group_type": "Active Comparator", 
                "description": "Calcineurin inhibitors maintenance"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators multicenter randomized open-labelled study will investigate the efficacy\n      of an everolimus based immunosuppression in reducing total native kidney volume in kidney\n      recipients with autosomal dominant polycystic kidney disease compared to a calcineurin\n      inhibitor-based immunosuppression."
        }, 
        "brief_title": "The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Autosomal Dominant Polycystic Kidney Disease", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Polycystic Kidney Diseases", 
                "Polycystic Kidney, Autosomal Dominant"
            ]
        }, 
        "detailed_description": {
            "textblock": "Kidney graft recipients receiving a firs kidney graft (between 6 months and 5 years\n      post-transplantation) will be randomized 1:1 to receive an everolimus based\n      immunosuppression (in association with steroids and mycophenolate mofetil) or to continue\n      their calcineurin inhibitor-based immunosuppression regimen. The primary objective will be\n      the reduction of total native kidney volume after a 2-years treatment period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age between 18 and 75 years-old\n\n          -  recipients of a first kidney graft between 6 month and 5 years ago with a stable eGFR\n             above 30 ml/min/1,73m2\n\n          -  contraception for female recipients to avoid pregnancy\n\n          -  valid health Insurance during the study period\n\n        Exclusion Criteria:\n\n          -  signed informed consent not obtained"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02134899", 
            "org_study_id": "P 090804", 
            "secondary_id": "2012-004265-41"
        }, 
        "intervention": [
            {
                "arm_group_label": "Everolimus", 
                "description": "Change from a calcineurin inhibitors-based immunosuppression to an everolimus-based immunosuppression", 
                "intervention_name": "Everolimus", 
                "intervention_type": "Drug", 
                "other_name": "everolimus conversion"
            }, 
            {
                "arm_group_label": "Calcineurin", 
                "description": "Usual treatment", 
                "intervention_name": "Calcineurin inhibitors maintenance", 
                "intervention_type": "Drug", 
                "other_name": "calcineurin-inhibitors based immunosuppression"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Everolimus", 
                "Sirolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Autosomal dominant polycystic kidney disease", 
            "cyst", 
            "kidney", 
            "liver", 
            "kidney transplantation", 
            "IF/TA", 
            "fibrosis", 
            "DSA", 
            "mTOR inhibitors", 
            "calcineurin inhibitors"
        ], 
        "lastchanged_date": "May 8, 2014", 
        "location": {
            "contact": {
                "email": "helene.francois@bct.aphp.fr", 
                "last_name": "H\u00e9l\u00e8ne Fran\u00e7ois", 
                "phone": "+33(1)45 21 27 22"
            }, 
            "facility": {
                "address": {
                    "city": "Le Kremlin-Bic\u00eatre", 
                    "country": "France", 
                    "zip": "94275"
                }, 
                "name": "Bic\u00eatre Hospital"
            }, 
            "investigator": {
                "last_name": "H\u00e9l\u00e8ne Fran\u00e7ois, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-labelled Multicenter Randomized Study on the Efficacy of Everolimus in Reducing Total Native Kidney Volume in Kidney Transplanted Patients With Autosomal Dominant Polycystic Kidney Disease", 
        "overall_contact": {
            "email": "helene.francois@bct.aphp.fr", 
            "last_name": "H\u00e9l\u00e8ne Fran\u00e7ois, MD, PhD", 
            "phone": "+33(1)45 21 27 22"
        }, 
        "overall_official": {
            "affiliation": "AP-HP", 
            "last_name": "H\u00e9l\u00e8ne Fran\u00e7ois, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "measurements of total native kidney volume with a MRI", 
            "measure": "Total native kidney volume variation", 
            "safety_issue": "No", 
            "time_frame": "24 months after randomization"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02134899"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Measurements of the biggest liver cyst volume with a MRI", 
                "measure": "Volume variation of the biggest liver cyst", 
                "safety_issue": "No", 
                "time_frame": "24 months after randomization"
            }, 
            {
                "description": "IF/TA quantification using Banff criteria during a kidney biopsy", 
                "measure": "Interstitial Fibrosis/Tubular Atrophy variation", 
                "safety_issue": "No", 
                "time_frame": "24 months after randomization"
            }, 
            {
                "description": "% fibrosis quantified using a morphometry software", 
                "measure": "% interstitial fibrosis using Red Sirius staining", 
                "safety_issue": "No", 
                "time_frame": "24 months after randomization"
            }, 
            {
                "description": "calculated estimated GFR", 
                "measure": "Calculated Estimated Glomerular Filtration rate", 
                "safety_issue": "No", 
                "time_frame": "At baseline, 1 month, 6 months, 12 months, 18 and 24 months"
            }, 
            {
                "description": "measured GFR", 
                "measure": "Measured Glomerular Filtration rate", 
                "safety_issue": "No", 
                "time_frame": "At baseline and 24 months"
            }, 
            {
                "description": "Measurement", 
                "measure": "Proteinuria", 
                "safety_issue": "No", 
                "time_frame": "At baseline, 1 month, 6 months, 12 months, 18 and 24 months"
            }, 
            {
                "description": "Clinic measurement", 
                "measure": "systolic and diastolic blood pressure", 
                "safety_issue": "No", 
                "time_frame": "At baseline, 1 month, 6 months, 12 months, 18 and 24 months"
            }, 
            {
                "description": "Measurements", 
                "measure": "Occurrence of diabetes or hyperlipidemia", 
                "safety_issue": "No", 
                "time_frame": "up to 24 months"
            }, 
            {
                "description": "Medical chart reporting", 
                "measure": "Occurrence of neoplasia", 
                "safety_issue": "No", 
                "time_frame": "up to 24 months"
            }, 
            {
                "description": "V0, 1 year and 2 years after randomization", 
                "measure": "Development of HLA Donor Specific Antibody (DSA)", 
                "safety_issue": "No", 
                "time_frame": "At baseline, 1 month, 6 months, 12 months, 18 and 24 months"
            }
        ], 
        "source": "Assistance Publique - H\u00f4pitaux de Paris", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Assistance Publique - H\u00f4pitaux de Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}